BACKGROUND: The US President's Emergency Plan for AIDS Relief (PEPFAR) has supported the extension of HIV care and treatment to 2.4 million individuals as of September 2009. With increasing resources targeted toward rapid scale-up, it is important to understand the characteristics of current PEPFAR-supported HIV care and treatment sites. METHODS: Forty-five sites in Botswana, Ethiopia, Nigeria, Uganda, and Vietnam were sampled. Data were collected retrospectively from successive 6-month periods through reviews of facility records and interviews with site personnel between April 2006 and March 2007. Facility size and scale-up rate, patient characteristics, staffing models, clinical and laboratory monitoring, and intervention mix were compared. RESULTS: Sites added a median of 293 patients per quarter. By the evaluation's end, sites supported a median of 1649 HIV patients, 922 of them receiving antiretroviral therapy. Patients were predominantly adult (97.4%), and the majority (96.5%) were receiving regimens based on nonnucleoside reverse transcriptase inhibitors. The ratios of physicians to patients dropped substantially as sites matured. Antiretroviral therapy patients were commonly seen monthly or quarterly for clinical and laboratory monitoring, with CD4 counts being taken at 6-month intervals. One-third of sites provided viral load testing. Cotrimoxazole prophylaxis was the most prevalent supportive service. CONCLUSIONS: HIV treatment sites scaled up rapidly with the influx of resources and technical support through PEPFAR, providing complex health services to progressively expanding patient cohorts. Human resources are stretched thin, and delivery models and intervention mix differ widely between sites. Ongoing research is needed to identify best-practice service delivery models.
BACKGROUND: The US President's Emergency Plan for AIDS Relief (PEPFAR) has supported the extension of HIV care and treatment to 2.4 million individuals as of September 2009. With increasing resources targeted toward rapid scale-up, it is important to understand the characteristics of current PEPFAR-supported HIV care and treatment sites. METHODS: Forty-five sites in Botswana, Ethiopia, Nigeria, Uganda, and Vietnam were sampled. Data were collected retrospectively from successive 6-month periods through reviews of facility records and interviews with site personnel between April 2006 and March 2007. Facility size and scale-up rate, patient characteristics, staffing models, clinical and laboratory monitoring, and intervention mix were compared. RESULTS: Sites added a median of 293 patients per quarter. By the evaluation's end, sites supported a median of 1649 HIV patients, 922 of them receiving antiretroviral therapy. Patients were predominantly adult (97.4%), and the majority (96.5%) were receiving regimens based on nonnucleoside reverse transcriptase inhibitors. The ratios of physicians to patients dropped substantially as sites matured. Antiretroviral therapy patients were commonly seen monthly or quarterly for clinical and laboratory monitoring, with CD4 counts being taken at 6-month intervals. One-third of sites provided viral load testing. Cotrimoxazole prophylaxis was the most prevalent supportive service. CONCLUSIONS: HIV treatment sites scaled up rapidly with the influx of resources and technical support through PEPFAR, providing complex health services to progressively expanding patient cohorts. Human resources are stretched thin, and delivery models and intervention mix differ widely between sites. Ongoing research is needed to identify best-practice service delivery models.
Authors: David M Moore; Jonathan Mermin; Anna Awor; Benita Yip; Robert S Hogg; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: Adrian R Levy; Douglas James; Karissa M Johnston; Robert S Hogg; P Richard Harrigan; Brian P Harrigan; Boris Sobolev; Julio S Montaner Journal: Lancet Infect Dis Date: 2006-03 Impact factor: 25.071
Authors: Samuel Abimerech Luboga; Bert Stover; Travis W Lim; Frederick Makumbi; Noah Kiwanuka; Flavia Lubega; Assay Ndizihiwe; Eddie Mukooyo; Erin K Hurley; Nagesh Borse; Angela Wood; James Bernhardt; Nathaniel Lohman; Lianne Sheppard; Scott Barnhart; Amy Hagopian Journal: Health Policy Plan Date: 2016-03-27 Impact factor: 3.344
Authors: Vivek Jain; Teri Liegler; Jane Kabami; Gabriel Chamie; Tamara D Clark; Douglas Black; Elvin H Geng; Dalsone Kwarisiima; Joseph K Wong; Mohamed Abdel-Mohsen; Nitin Sonawane; Francesca T Aweeka; Harsha Thirumurthy; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: Clin Infect Dis Date: 2012-12-12 Impact factor: 9.079
Authors: Mark M Manak; Ogbonnaya S Njoku; Ashley Shutt; Jennifer Malia; Linda L Jagodzinski; Mark Milazzo; Aminu Suleiman; Amos A Ogundeji; Robert Nelson; Ojor R Ayemoba; Robert J O'Connell; Darrell E Singer; Nelson L Michael; Sheila A Peel Journal: J Clin Microbiol Date: 2015-08-26 Impact factor: 5.948
Authors: Stephany N Duda; Amanda M Farr; Mary Lou Lindegren; Meridith Blevins; C William Wester; Kara Wools-Kaloustian; Didier K Ekouevi; Matthias Egger; Jennifer Hemingway-Foday; David A Cooper; Richard D Moore; Catherine C McGowan; Denis Nash Journal: J Int AIDS Soc Date: 2014-12-15 Impact factor: 5.396
Authors: Shahira Ahmed; Till Bärnighausen; Norman Daniels; Richard Marlink; Marc J Roberts Journal: Implement Sci Date: 2016-02-11 Impact factor: 7.327
Authors: Echezona E Ezeanolue; Michael C Obiefune; Wei Yang; Stephen K Obaro; Chinenye O Ezeanolue; Gbenga G Ogedegbe Journal: Implement Sci Date: 2013-06-08 Impact factor: 7.327